참고문헌
- Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-5. https://doi.org/10.1161/01.CIR.0000072767.89944.6E
- Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa (dabigatran etexilate) package insert. Ridgefield, CT: Author; 2011.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. https://doi.org/10.1056/NEJMoa0905561
- Lal Y, Van Heukelom J. Dabigatran: a cause of hematologic emergency. Am J Med Sci 2013;346:190-3. https://doi.org/10.1097/MAJ.0b013e31826c5a56
- Nyby S, Hennes O. Fatal bleeding diarrhoea during dabigatran etexilate therapy. Ugeskr Laeger 2014;176. pii: V09140482.
- Dy EA, Shiltz DL. Hemopericardium and cardiac tamponade associated with dabigatran use. Ann Pharmacother 2012;46:e18. https://doi.org/10.1345/aph.1R112
- Barton CA, McMillian WD, Raza SS, Keller RE. Hemopericardium in a patient treated with dabigatran etexilate. Pharmacotherapy 2012;32:e103-7. https://doi.org/10.1002/j.1875-9114.2012.01036.x
- Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72. https://doi.org/10.1161/CIRCULATIONAHA.110.004747
- Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95. https://doi.org/10.2165/00003088-200847050-00001
- Kernan L, Ito S, Shirazi F, Boesen K. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol (Phila) 2012;50:571-3. https://doi.org/10.3109/15563650.2012.705290
- Lindahl TL, Baghaei F, Blixter IF, et al; Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371-8. https://doi.org/10.1160/TH10-06-0342
- Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107:985-97. https://doi.org/10.1160/TH11-11-0804
- Kim J, Yadava M, An IC, et al. Coagulopathy and extremely elevated PT/INR after dabigatran etexilate use in a patient with end-stage renal disease. Case Rep Med 2013;2013:131395.
- van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27. https://doi.org/10.1160/TH09-11-0758
피인용 문헌
- Dabigatran etexilate overdose : Hemopericardium, cardiac tamponade and INR elevation: case report vol.1590, pp.1, 2016, https://doi.org/10.1007/s40278-016-15131-5
- First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab vol.2017, pp.None, 2016, https://doi.org/10.1155/2017/6458636
- Dabigatran-Induced Spontaneous Hemopericardium and Cardiac Tamponade vol.44, pp.5, 2016, https://doi.org/10.14503/thij-16-6073
- Uma Combinação Fatal: Indometacina e Dabigatrana vol.114, pp.4, 2016, https://doi.org/10.36660/abc.20180159
- Vitamin K deficiency-induced spontaneous haemopericardium and cardiac tamponade in an infant with alpha-1 antitrypsin deficiency: a case report vol.5, pp.1, 2021, https://doi.org/10.1093/ehjcr/ytaa481